CMC Biologics global chief operations officer Gustavo Mahler said the company looks forward to working with MacroGenics to further develop and advance this immuno-oncology program.
"This contract highlights CMC Biologics’ focus on working with our customers as partners and our capabilities in the development and clinical manufacturing of monoclonal antibodies," Mahler said.
MacroGenics president and chief executive officer Scott Koenig said the company is impressed with CMC Biologics’ experience and technical competency in biopharmaceutical development and cGMP manufacturing.
"Choosing a contract manufacturing partner with quality facilities that is able to provide flexible solutions and meet our clinical timelines is critical to realizing the potential of life-saving medicines," Koenig said.
CMC Biologics has three facilities in the US and Europe, and it offers fully integrated biopharmaceutical development and manufacturing solutions to clients globally.
The company also has expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production.
The company’s integrated services include cell line development, bioprocess development, formulation and comprehensive analytical testing.